Abstract
RNA interference (RNAi) is a natural cellular process that regulates gene expression by silencing specific messenger RNAs (mRNAs), thereby preventing the translation of genes into proteins. RNAi has emerged as a promising tool for pharmaceutical applications, enabling the targeted suppression of disease-related genes, including those involved in cancer, viral infections, genetic disorders, and autoimmune diseases. This article explores the potential of RNAi as a therapeutic approach, highlighting its mechanisms, challenges, and progress in clinical applications. Despite the therapeutic promise, several hurdles such as efficient delivery systems, off-target effects, and long-term safety remain. The future of RNAi-based therapeutics will likely depend on overcoming these challenges and optimizing RNAi delivery techniques.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.